Pelvalon today announced new data on the LIFE study of the Eclipse System to be presented by Dr. Isuzu Meyer at the Pelvic Floor Disorders (PFD) Week 2017, which is taking place October 3-7 at the Rhode Island Convention Center in Providence.
The LIFE study, previously published in Obstetrics & Gynecology, was the pivotal trial of this first-of-its-kind treatment for women experiencing loss of bowel control that supported FDA clearance of the device.
PFD Week 2017 is the 38th Annual Scientific Meeting of the American Urogynecologic Society (AUGS), and highlights the importance of education on pelvic floor disorders, which impact one in three women. Loss of bowel control is a pelvic floor disorder, often called accidental bowel leakage (ABL) or fecal incontinence (FI). The condition can be caused by pregnancy, childbirth, nerve or muscle damage in the pelvic region, or other gastrointestinal conditions.
Dr. Isuzu Meyer, Assistant Professor of Obstetrics and Gynecology at the University of Alabama Birmingham, presents her results on Thursday, October 5th, at 8:37am in Ballroom C at PFD Week. The study compared treatment efficacy of the Eclipse System on patients with different subtypes of fecal incontinence.